Recent progress in the development of assays suited for histone deacetylase inhibitor screening

Molecular Genetics and Metabolism

Volumn 80, Issue 1-2, 2003, Pages 138-147

  Wegener, Dennis ^a   Hildmann, Christian ^a   Schwienhorst, Andreas ^a  

^a Inst fuer Mikrobiologie und Genetik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; M 232; MD 85; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANALYTIC METHOD; AUTOMATION; BIOASSAY; BIOTECHNOLOGY; CELL ASSAY; CELL CULTURE; COST EFFECTIVENESS ANALYSIS; DRUG DETERMINATION; ENZYME ASSAY; ENZYME SUBSTRATE; FLUORESCENCE; GENE ACTIVATION; GENETIC ANALYSIS; HUMAN; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; SCREENING; SENSITIVITY ANALYSIS; SHORT SURVEY; STANDARD; TECHNOLOGY;

EID: 0142121314     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymgme.2003.08.008     Document Type: Short Survey

References (80)

1. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA. 51:1964;786-794.
2. Hebbes T.R., Thorne A.W., Crane-Robinson C. A direct link between core histone acetylation and transcriptionally active chromatin. J. EMBO. 7:1988;1395-1402.
3. Gross D.S., Garrard W.T. Nuclease hypersensitive sites in chromatin. Ann. Rev. Biochem. 57:1988;159-197.
4. Vidali G., Ferrari N., Pfeffer U. Histone acetylation: a step in gene activation. Adv. Exp. Med. Biol. 231:1988;583-596.
5. Norton V.G., Imai B.S., Yau P., Bradbury E.M. Histone acetylation reduces nucleosome core particle linking number change. Cell. 57:1989;449-457.
6. Norton V.G., Marvin K.W., Yau P., Bradbury E.M. Nucleosome linking number change controlled by acetylation of histones H3 and H4. J. Biol. Chem. 265:1990;19848-19852.
7. Chung D. Histone modification: the next wave in cancer therapeutics. Trends Mol. Med. 8:2002;S10-S11.
8. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
9. Wade P.A., Pruss D., Wolffe A.P. Histone acetylation: chromatin in action. Trends Biochem. Sci. 22:1997;128-132.
10. Peterson C.L. HDAC's at work: everyone doing their part. Mol. Cell. 9:2002;921-929.
11. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:2003;151-163.
12. Grozinger C.M., Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9:2002;3-16.
13. Siddique H., Zhou J.P., Rao V.N., Reddy E.S. The BRCA2 is a histone acetyltransferase. Oncogene. 16:1998;2283-2285.
14. Lin R.J., Nagy L., Inoue S., Shao W., Miller V.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814.
15. Grignani F., DeMatteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Grignani F., Lazar M.A., Minucci S., Pelicci P.G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818.
16. Warrell R.P., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1998;1621-1625.
17. Zhang Y., LeRoy G., Seelig H.P., Lane W.S., Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 95:1998;279-289.
18. Yoshida M., Horinouchi S., Beppu T. Trichostatin A trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 17:1995;423.
19. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
20. Jung M., Brosch G., Kolle D., Scherf H., Gerhausen C., Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42:1999;4669-4679.
21. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:1998;126-132.
22. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tusruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 96:1999;4592-4597.
23. Saunders N., Dicker A., Popa C., Jones S., Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 59:1999;399-404.
24. Schmidt K., Gust R., Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch. Pharm. 332:1999;353-357.
25. Zhou Q., Melkoumian Z.K., Lucktong A., Moniwa M., Davie J.R., Strobl J.S. Rapid induction of histone acetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem. 275:2000;35256-35263.
26. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemotherapy Pharmacol. 48(Suppl 1):2001;S20-S26.
27. Kramer O.H., Gottlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12:2001;294-306.
28. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. 1:2002;287-299.
29. V. Richon, C. Berrie, Histone deacetylase inhibitors - Redefining pharmaceutical approaches to the treatment of cancer. LeadDiscovery, 2002.
30. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., Schmatz D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA. 93:1996;13143-13147.
31. Li X., Uchiyama T., Raetz C.R., Hindsgaul O. Synthesis of a carbohydrate-derived hydroxamic acid inhibitor of the enzyme (LpxC) involved in lipid A biosynthesis. Org. Lett. 20:2003;539-541.
32. Klan N., Seuter S., Schnur N., Jung M., Steinhilber D. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biol. Chem. 384:2003;777-785.
33. Kölle D., Brosch G., Lechner T., Lusser A., Loidl P. Biochemical methods for analysis of histone deacetylases. Methods. 15:1998;323-331.
34. Kijma M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irresversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268:1993;22429-22435.
35. Emiliani S., Fischle W., VanLint C., Al-abed Y., Verdin E. Characterization of a human RPD3 ortholog HDAC3. Proc. Natl. Acad. Sci. USA. 95:1998;2795-2800.
36. Hendzel M.J., Delcuve G.P., Davie J.R. Histone deacetylase is a component of the internal nuclear matrix. J. Biol. Chem. 266:1991;21936-21942.
37. Sendra R., Rodrigo I., Salvador M.L., Franco L. Characterization of pea-histone deacetylases. Plant Mol. Biol. 11:1988;857-866.
38. Kervabon A., Mery J., Parello J. Enzymatic deacetylation of a synthetic peptide fragment of histone H4. FEBS Lett. 106:1979;93-96.
39. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 272:1996;408-411.
40. Kwon H.J., Owa T., Hassig C.A., Shimada J., Schreiber S.L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA. 95:1998;3356-3361.
41. Nare B., Alloco J.J., Kuningas R., Galuska S., Myers R.W., Bednarek M.A., Schmatz D.M. Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide derived from histone-H4. Anal. Biochem. 267:1999;390-396.
42. Hoffmann K., Brosch G., Loidl P., Jung M. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res. 27:1999;2057-2058.
43. Wegener D., Wirsching F., Riester D., Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10:2003;61-68.
44. Hoffmann K., Brosch G., Loidl P., Jung M. First non-radioactive assay for in vitro screening of histone deacetylase. Pharmazie. 55:2000;601-606.
45. Hoffmann K., Söll R.M., Beck-Sickinger A.G., Jung M. Fluorescence-labeled octapeptides as substrates for histone deacetylase. Bioconj. Chem. 12:2001;51-55.
46. Hoffmann K., Heltweg B., Jung M. Improvement and validation of the fluorescence-based histone deacetylase assay using an internal standard. Arch. Pharm. Pharm. Med. Chem. 334:2001;248-252.
47. Heltweg B., Jung M. A microplate reader-based nonisotopic histone deacetylase activity assay. Anal. Biochem. 302:2002;175-183.
48. Heltweg B., Jung M. Eosin Y as an internal standard for a plate reader-based quantitation of a histone deacetylase substrate. Arch. Pharm. Pharm. Med. Chem. 6:2002;296-300.
49. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol. Bioeng. 61:1998;61-67.
50. D. Wegener, C. Hildmann, D. Riester, A. Schwienhorst, Improved fluorogenic histone deacetylase assay for high-throughput-screening applications, Anal. Biochem. 321 (2003) in press.
51. Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4:1999;67-73.
52. Grahn S., Ullmann D., Jakubke H.-D. Design and synthesis of fluorogenic trypsin peptide substrates based on resonance energy transfer. Anal. Biochem. 265:1998;225-231.
53. Koltermann A., Kettling U., Bieschke J., Winkler T., Eigen M. Rapid assay processing by integration of dual-color fluorescence cross-correlation spectroscopy: high-throughput screening for enzyme activity. Proc. Natl. Acad. Sci. USA. 95:1998;1421-1426.
54. Heltweg B., Jung M. A homogeneous nonisotopic histone deacetylase activity assay. J. Biomol. Screen. 8:2003;89-95.
55. Udenfriend S., Stein S., Böhlen P., Dairman W., Leimgruber W., Weigele P. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science. 178:1972;871-872.
56. Schwienhorst A. Advanced screening strategies for biocatalyst discovery. Brakmann S., Johnsson K. Directed Molecular Evolution of Proteins. 2002;159-176 Wiley-VCH Verlag, Weinheim.
57. C. Hildmann, M. Ninkovic, R. Dietrich, D. Riester, D. Wegener, T. Zimmermann, O.M. Birch, C. Bernegger, P. Loidl, A. Schwienhorst, A novel amidohydrolase from Bordetella/Alcaligenes strain FB188 with similarities to histone deacetylases, J. Bacteriol. (2003), submitted.
58. Wang W., Maniar M., Jain R., Jacobs J., Trias J., Yuan Z. A fluorescence-based homogeneous assay for measuring activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase. Anal. Biochem. 290:2001;338-346.
59. Baumann M., Stürmer R., Bornscheuer U.T. A high-throughput-screening method for the identification of enantioselective hydrolases. Angew. Chem. Int. Ed. Engl. 40:2001;4201-4204.
60. Kim Y., Tanner K.G., Denu J.M. A continuous, nonradioactive assay for histone acetyltransferase. Anal. Biochem. 280:2000;308-314.
61. Palo K., Mets U., Jager S., Kask P., Gall K. Fluorescence intensity multiple distributions analysis: concurrent determination of diffusion times and molecular brightness. Biophys. J. 79:2000;2858-2866.
62. Eggeling C., Fries J.R., Brand L., Günther R., Seidel C.A.M. Monitoring conformational dynamics of a single molecule by selective fluorescence spectroscopy. Proc. Natl. Acad. Sci. USA. 95:1998;1556-1561.
63. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6:1999;71.
64. Haggarty S.J., Koehler K.M., Wong J.C., Butcher R.A., Schreiber S.L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10:2003;383-396.
65. Koeller K.M., Haggarty S.J., Perkins B.D., Leykin I., Wong J.C., Kao M.-C.J., Schreiber S.L. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem. Biol. 10:2003;397-410.
66. Kamitani H., Taniura S., Ikawa H., Watanabe T., Kelavkar U.P., Eling T.E. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis. 22:2001;187-191.
67. Xiao H., Hasegawa T., Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73:1999;291-302.
68. Huang L., Sowa Y., Sakai T., Pardee A.B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene. 19:2000;5712-5719.
69. Remiszewski S.W., Sambucetti L.C., Atadja P., Bair K.W., Cornell W.D., Green M.A., Howell K.L., Jung M., Kwon P., Trogani N.et al. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 45:2002;753-757.
70. Su G.H., Sohn T.A., Ryu B., Kern S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60:2000;3137-3142.
71. Whitman M. Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev. 12:1998;2445-2462.
72. Pouponnot C., Jayananan L., Massague J. Physical and functional interaction of SMADS and p300/CBP. J. Biol. Chem. 273:1998;22865-22868.
73. Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276:2001;38837-38843.
74. MacBeath K., Koehler A.N., Schreiber S.L. Printing small molecules as microarrays and detecting protein-ligand interactions en masse. J. Am. Chem. Soc. 121:1999;7967-7968.
75. MacBeath K., Schreiber S.L. Printing proteins as microarrays for high-throughput function determination. Science. 289:2000;1760-1763.
76. Robyr D., Suka Y., Xenarios I., Kurdistani S.K., Wang A., Suka N., Grunstein M. Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell. 109:2002;437-446.
77. Hu E., Chen Z., Fredrickson T., Zhu Q., Krikpatrick R., Zhang G.-F., Johanson K., Sung C.-M., Liu R., Winkler J. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcriptional repressor. J. Biol. Chem. 275:2000;15254-15264.
78. Marmorstein R. Structure of histone deacetylases: insights into substrate recognition and catalysis. Structure. 9:2001;1127-1133.
79. D. Riester, F. Wirsching, G. Salinas, M. Keller, M. Gebinoga, S. Kamphausen, C. Merkwart, R. Goetz, M. Wiesenfeldt, J. Stürzebecher, M. Thürk, A. Schwienhorst, Novel thrombin inhibitors identified by computer-assisted multiparameter design (2003), submitted.
80. Suzuki T., Ando T., Tsuchiya K., Fukazawa N. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42:1999;3001-3003.